We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -1.02% | 48.50 | 48.00 | 49.00 | 48.75 | 47.50 | 48.75 | 1,572,430 | 12:18:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.53 | 138.26M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/4/2019 13:09 | Just to remind everybody Moderna is presenting today at the Needham conference | hampton58 | |
09/4/2019 17:21 | yes, I do believe they will young man :-) cheers Wan lol | wanobi | |
09/4/2019 16:59 | Jam, jam and more jam but will they ever deliver!? | killieboy | |
09/4/2019 15:02 | The mRNA platform is a promising medical technology which have attracted a wave of interest and partnerships from the majors and with Moderna now taking the partnership with Avacta forward , exciting times ahead.The sector will push valuations up and Astra Zeneca Merck,Sanofi etc are investing.Watch this space. | hampton58 | |
09/4/2019 14:53 | Interesting reaction to today's results.With Details of the upfront payment from LG Chem license agreement and clearly further license deals in the pipeline, combined this with the recent confirmation of Moderna having exercised its option to take the license agreement further, makes this mRNA play a very attractive area to be involved in.The mRNA equities, Moderna etc have had a significant uplift over the last couple of weeks. Moderna is up +35% in the last week or so.Recent publications in prestigious journals, shows that if it is proven that the mRNA encoded protein synthesis works in animals is extended to humans, a $200 billon recombinant protein industry is being disrupted.Previous data have shown Affimets seem to be good for encoded delivery. | hampton58 | |
09/4/2019 10:51 | "Plenty of cash in the bank"...plenty of cash to come, look at the ridiculous market cap and DYOR. | 1i1i1i | |
09/4/2019 10:49 | hxxps:// www.proactiveinvesto Avacta well-cashed and on track to begin clinical trial of first Affimer therapeutic next year 11:40 09 Apr 2019 The first Affimer-based therapeutic is PD-L1 is a potential cancer treatment that helps the immune system to identify and attack cancer cells Affimers have both therapeutic and non-therapeutic uses Avacta Group PLC (LON:AVCT) remains on track to begin a Phase I clinical trial of its first Affimer therapeutic candidate next year. Affimers are small, engineered proteins that are capable of binding specific molecular targets, in a similar way to antibodies. READ: Avacta says partner Moderna takes collaboration to next level The proteins are smaller, quicker to manufacture and easier to format than antibodies, but they maintain antibody-like biologic activity when binding a target. Avacta thinks the technology has both therapeutic and non-therapeutic applications. The AIM company is already using Affimers to develop various potential cancer treatments, while other companies pay to use the technology in their research and diagnostics. Avacta has selected a PD-L1 inhibitor as the first Affimer-based potential cancer therapeutic that it is taking through the clinic. PD-L1 is a checkpoint protein that essentially provides a cloak for the cancer cells, helping them to evade detection by the immune system. Start dosing in Q4 2020 The company is soon to start manufacturing its PD-L1 inhibitor – called AVA004-251 – which will then allow it to file a clinical trial application, asking regulators to let it test the drug on humans. That filing is expected to happen in late 2020 and the plan is to start dosing the first patients in a Phase I dose escalation study in the final quarter of next year. “The group remains focused on the key objective of first-time-in-human data for the Affimer therapeutic programme and growing a profitable Affimer reagents business,” said chief executive Alastair Smith. “First-time-in Plenty of cash in the bank For the six months ended 31 January, Avacta recorded revenues of £1.0mln (H1 18: £1.5mln), although the new licensing deal with LG Chem will boost second-half numbers. Unsurprisingly, R&D costs rose to £2.4mln (H1 18: £1.5mln) in the period, which meant operating losses climbed to £5.9mln (H1 18: £4.5mln). Thanks to an £11.6mln fundraise in August, cash on hand totalled £11.8mln at the end of January (H1 18: £5.2mln). In a note to clients, analysts at ‘house’ broker finnCap commented: “Significant progress continues to be made in non-therapeutic applications that include at least two in-house diagnostic assay development programmes with further licence | 1i1i1i | |
09/4/2019 08:47 | Then move on Poacher, $2.5m received, $5.5m due in the near term, cash in the bank and multiple deals in the pipeline, good enough for me. | 1i1i1i | |
09/4/2019 08:39 | Was it 10 years ago they forcast a profit for the next year. Still the same old story turnover lower or stagnated. Losses higher every year. Always jam tommorrow. | poacher45 | |
09/4/2019 07:55 | How much lower will it go.. fancy a top up. | losses | |
09/4/2019 07:30 | Typical short termism... buying opportunity. | bonzo | |
09/4/2019 07:28 | Results didn't go down well.. | losses | |
09/4/2019 07:28 | Slower progress than hoped for - Not liked by market - Down 10% - Long term jury still out - Could be some more profit preservation to come by those who took part in the placing (imo) | pugugly | |
09/4/2019 06:21 | "Strong focus on generating further license deals during 2019 arising from multiple ongoing technology evaluations." I like the word multiple ;-) | 1i1i1i | |
09/4/2019 06:18 | Less upfront ($2.5m) and near term ($5.5m) than I'd hoped for in a $300m deal, but as the first deal it provides a baseline for future deals. Remains the most likely 100-bagger in my portfolio, though obviously has the associated risks of any fledgling biotech. Market cap is still nothing more than pocket change to large pharma. | the drewster | |
08/4/2019 15:32 | Not correct At the AGM the company mentioned that they would not release details of the upfront payment until interims numbers.ie. tomorrow So we should more details tomorrow. | hampton58 | |
08/4/2019 15:06 | I thought LG had requested no detail be released so I don't expect to read anything new tomorrow. | toffeeman | |
08/4/2019 14:56 | In the initial RNS they mentioned an upfront payment , but more important there would further near term milestone paymentsShould be very interesting tomorrow AM | hampton58 | |
08/4/2019 14:47 | Keeping these next 4-5 years | losses | |
08/4/2019 14:26 | They said so verbally at at least one of the presentations. | the drewster | |
08/4/2019 14:20 | Did they say somewhere that further detail on the deal with LG would be disclosed in the results? | mortimer7 | |
08/4/2019 13:21 | YesShould see further upside tomorrow testing March highs | zebrano10 | |
08/4/2019 10:50 | Looking perky this morning. | losses | |
08/4/2019 09:00 | YesWill be Interesting read indeedI suspect additional ongoing talks are taking place with other parties generating potential further contractsCould be a good day tomorrow | zebrano10 | |
08/4/2019 08:35 | Results tomorrow which will include the LG payment. | 1i1i1i |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions